

In-Hospital Switching Between Clopidogrel and Prasugrel in Patients With Acute Myocardial Infarction Treated With Percutaneous Coronary Intervention

Circulation: Cardiovascular Interventions
2014;7:585-593

DOI: [10.1161/circinterventions.114.001555](https://doi.org/10.1161/circinterventions.114.001555)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Pharmacodynamic and Clinical Implications of Switching Between P2Y12 Receptor Antagonists. Critical Pathways in Cardiology, 2014, 13, 156-158.	0.5	9
2	The Association of Previous Revascularization With In-Hospital Outcomes in Acute Myocardial Infarction Patients. JACC: Cardiovascular Interventions, 2015, 8, 1954-1962.	2.9	14
3	Prasugrel in Clopidogrel Nonresponders. JACC: Cardiovascular Interventions, 2015, 8, 1571-1573.	2.9	1
4	Dual antiplatelet therapy: optimal timing, management, and duration. European Heart Journal - Cardiovascular Pharmacotherapy, 2015, 1, 198-204.	3.0	32
5	Controversies in Cardiology. , 2015, , .		0
6	Switching between thienopyridines in patients with acute myocardial infarction and quality of care. Open Heart, 2016, 3, e000384.	2.3	9
7	Effect of prior clopidogrel use on outcomes in medically managed acute coronary syndrome patients. Heart, 2016, 102, 1221-1229.	2.9	3
8	Assessment of P2Y12 inhibitor usage and switching in acute coronary syndrome patients undergoing percutaneous coronary revascularization. International Journal of Cardiology, 2016, 223, 854-859.	1.7	10
10	Transition between ticagrelor and two different doses of clopidogrel at hospital discharge in patients with acute coronary syndrome submitted to percutaneous coronary intervention. Revista Brasileira De Cardiologia Invasiva (English Edition), 2016, 24, 30-34.	0.1	0
11	Switching between ticagrelor and clopidogrel in patients who underwent percutaneous coronary intervention: insight into contemporary practice in Chinese patients. European Heart Journal Supplements, 2016, 18, F19-F26.	0.1	15
12	Switching of platelet P2Y12 receptor inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention: Review of the literature and practical considerations. American Heart Journal, 2016, 176, 44-52.	2.7	23
13	In-hospital switching from clopidogrel to prasugrel following thrombolysis for ST-elevation myocardial infarction: a 3-year single center experience. European Heart Journal: Acute Cardiovascular Care, 2016, 5, 271-276.	1.0	1
14	The impact of switching P2Y12 receptor inhibitor therapy during index hospitalization: a systematic review. European Journal of Clinical Pharmacology, 2016, 72, 83-91.	1.9	6
15	Switching P2Y12-receptor inhibitors in patients with coronary artery disease. Nature Reviews Cardiology, 2016, 13, 11-27.	13.7	154
16	Use of prasugrel vs clopidogrel and outcomes in patients with acute coronary syndrome undergoing percutaneous coronary intervention in contemporary clinical practice: Results from the PROMETHEUS study. American Heart Journal, 2017, 188, 73-81.	2.7	25
17	Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of Tj ETQq1 1 0.784314 rgBT /Overl 38, 3070-3078.	2.2	316
18	Switching P2Y12 Receptor Inhibiting Therapies. Interventional Cardiology Clinics, 2017, 6, 67-89.	0.4	10
19	Association of measured platelet reactivity with changes in P2Y 12 receptor inhibitor therapy and outcomes after myocardial infarction: Insights into routine clinical practice from the Treatment with ADP receptor iNhibitorS: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS) study. American Heart Journal. 2017. 187. 19-28.	2.7	14

#	ARTICLE	IF	CITATIONS
20	International Expert Consensus on Switching Platelet P2Y ₁₂ Receptor Inhibiting Therapies. <i>Circulation</i> , 2017, 136, 1955-1975.	1.6	293
21	In-stent thrombosis when switching ticagrelor to clopidogrel after percutaneous coronary intervention. <i>Platelets</i> , 2017, 28, 305-309.	2.3	1
22	Switching of adenosine diphosphate receptor inhibitor after hospital discharge among myocardial infarction patients: Insights from the Treatment with Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS) observational study. <i>American Heart Journal</i> , 2017, 183, 62-68.	2.7	60
23	Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial. <i>Lancet</i> , The, 2017, 390, 1747-1757.	13.7	443
24	Antiplatelet Therapy Changes for Patients With Myocardial Infarction With Recurrent Ischemic Events: Insights Into Contemporary Practice From the TRANSLATE-ACS (Treatment With ADP Receptor) Tj ETQq0.0.0 rgBT /Overlock 1	3.7	2
25	Impact of Chronic Antiplatelet Therapy on Infarct Size and Bleeding in Patients With Acute Myocardial Infarction. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2018, 23, 407-413.	2.0	2
26	Early P2Y ₁₂ Inhibitors Escalation in Primary PCI Patients: Insights from the RENOVAMI Registry. <i>Thrombosis and Haemostasis</i> , 2018, 118, 852-863.	3.4	0
27	Associations Between Complex PCI and Prasugrel or Clopidogrel Use in Patients With Acute Coronary Syndrome Who Undergo PCI: From the PROMETHEUS Study. <i>Canadian Journal of Cardiology</i> , 2018, 34, 319-329.	1.7	22
28	2018 Canadian Cardiovascular Society/Canadian Association of Interventional Cardiology Focused Update of the Guidelines for the Use of Antiplatelet Therapy. <i>Canadian Journal of Cardiology</i> , 2018, 34, 214-233.	1.7	181
29	Antiplatelet Therapy in ACS Patients: Comparing Appropriate P2Y ₁₂ Inhibition by Clopidogrel to the Use of New P2Y ₁₂ Inhibitors. <i>Journal of Atherosclerosis and Thrombosis</i> , 2018, 25, 674-689.	2.0	3
30	Studies on drug switchability showed heterogeneity in methodological approaches: a scoping review. <i>Journal of Clinical Epidemiology</i> , 2018, 101, 5-16.	5.0	2
31	P2Y ₁₂ inhibitors for the treatment of acute coronary syndrome patients undergoing percutaneous coronary intervention: current understanding and outcomes. <i>Expert Review of Cardiovascular Therapy</i> , 2019, 17, 717-727.	1.5	4
32	Switching between P2Y ₁₂ antagonists â€œ From bench to bedside. <i>Vascular Pharmacology</i> , 2019, 115, 1-12.	2.1	8
33	De-escalation of anti-platelet therapy in patients with acute coronary syndromes undergoing percutaneous coronary intervention. <i>Chinese Medical Journal</i> , 2019, 132, 197-210.	2.3	11
34	De-Escalation of Treatment With Oral P2Y ₁₂ Receptor Inhibitors: Current Status and Perspectives. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2019, 24, 304-314.	2.0	4
35	Switching of Oral P2Y ₁₂ Inhibitor Treatment in Patients with Acute Coronary Syndrome: Prevalence, Predictors, and Prognosis. <i>Clinical Drug Investigation</i> , 2019, 39, 275-283.	2.2	1
36	De-escalation versus standard dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis. <i>Platelets</i> , 2020, 31, 15-25.	2.3	13
37	Frequency and clinical outcomes of CYP2C19 genotype-guided escalation and de-escalation of antiplatelet therapy in a real-world clinical setting. <i>Genetics in Medicine</i> , 2020, 22, 160-169.	2.4	41

#	ARTICLE	IF	CITATIONS
38	Prospective <i>CYP2C19</i> Genotyping to Guide Antiplatelet Therapy Following Percutaneous Coronary Intervention. Circulation Genomic and Precision Medicine, 2020, 13, e002640.	3.6	39
39	Impact of Implementing CYP2C19 Genotype-Guided Antiplatelet Therapy on P2Y12 Inhibitor Selection and Clinical Outcomes in Acute Coronary Syndrome Patients After Percutaneous Coronary Intervention: A Real-World Study in China. Frontiers in Pharmacology, 2020, 11, 582929.	3.5	13
40	Ticagrelor Utilization in Patients With Non-ST Elevation Acute Coronary Syndromes in Romania. American Journal of Therapeutics, 2021, 28, e271-e283.	0.9	0
41	Antithrombotic therapy after percutaneous coronary intervention of bifurcation lesions. EuroIntervention, 2021, 17, 59-66.	3.2	21
42	Characteristics and clinical outcomes of patients with de-escalation from prasugrel to clopidogrel after acute myocardial infarction - Insights from the prospective Japan Acute Myocardial Infarction Registry (JAMIR) -. Journal of Cardiology, 2021, 78, 99-106.	1.9	3
43	Incidence and outcome of switching of oral platelet P2Y12 receptor inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention: the SCOPE registry. EuroIntervention, 2017, 13, 459-466.	3.2	83
44	DAPT After Stenting in Stable and Acute Coronary Syndromes- Does the Drug Combination Really Matter?. , 2015, , 255-269.		0
45	Antiplatelet Therapy in Acute Coronary Syndrome. Sklifosovsky Journal Emergency Medical Care, 2022, 10, 769-777.	0.6	0
46	Predictors and long-term outcomes of in-hospital switching from clopidogrel to ticagrelor among patients with acute coronary syndrome undergoing percutaneous coronary intervention. Catheterization and Cardiovascular Interventions, 2022, , .	1.7	0
47	Predictors of in-hospital de-escalation of P2Y12 inhibitors to clopidogrel in patients with acute myocardial infarction treated with percutaneous coronary intervention. Cardiovascular Revascularization Medicine, 2022, , .	0.8	1
48	Safety and Efficacy of Selective, Clopidogrel-Based Strategies in Acute Coronary Syndrome: A Study-Level Meta-analysis. Thrombosis and Haemostasis, 2022, 122, 1732-1743.	3.4	4
49	De-escalation of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients With Acute Coronary Syndrome: An Updated Meta-analysis and Trial Sequential Analysis of 21 Studies and 38,741 Patients. Journal of Cardiovascular Pharmacology, 2022, 79, 873-886.	1.9	1